BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 11, 2015--
Aimmune Therapeutics, Inc., today announced the closing of its initial
public offering of 11,499,999 shares of its common stock at a public
offering price of $16.00 per share, before underwriting discounts and
commissions, which includes the exercise in full by the underwriters of
their option to purchase up to an additional 1,499,999 shares of common
stock. Aimmune’s common stock began trading on The NASDAQ Global Select
Market on August 6, 2015, under the symbol AIMT.
BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as joint
book-running managers for the offering.
A registration statement relating to the securities was declared
effective by the Securities and Exchange Commission on August 5, 2015.
The offering of these securities was made only by means of a prospectus,
copies of which may be obtained from: BofA Merrill Lynch, Attention:
Prospectus Department, 222 Broadway, New York, NY 10038, or by emailing firstname.lastname@example.org;
Credit Suisse Securities (USA) LLC, Attention: Prospectus Department,
One Madison Avenue, New York, NY 10010, or by calling (800) 221-1037, or
by emailing email@example.com;
or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet
Mall, J12S03, Minneapolis, MN 55402, or by calling (800) 503-4611, or by
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification of these securities under the securities laws of any such
state or jurisdiction.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., founded in 2011 as Allergen Research
Corporation (ARC), is a clinical-stage biopharmaceutical company
developing treatments for peanut allergy and other food allergies.
Aimmune Therapeutics’ characterized oral desensitization immunotherapy
(CODIT™) system, an approach to oral immunotherapy (OIT), uses
rigorously characterized product candidates with gradual, controlled
up-dosing protocols to obtain clinically meaningful desensitization to
food allergens. Aimmune Therapeutics recently completed a Phase 2 study
of its lead product, AR101, a complex mixture of naturally occurring
proteins and pharmaceutical-grade ingredients for the treatment of
peanut allergy, one of the most common food allergies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150811006342/en/
Source: Aimmune Therapeutics, Inc.
Amanda Breeding, 415-229-7649